Denali Therapeutics Inc. (DNLI) Free cash flow 2016–2025
Denali Therapeutics Inc. (DNLI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$422.1MFY2025 · since FY2016: -$78.0M → -$422.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$422.1M | -16.1% |
| FY2024 | -$363.6M | +2.0% |
| FY2023 | -$370.9M | -41.3% |
| FY2022 | -$262.5M | -19.4% |
| FY2021 | -$219.9M | -153.2% |
| FY2020 | $413.1M | +343.7% |
| FY2019 | -$169.5M | -462.8% |
| FY2018 | $46.7M | +158.8% |
| FY2017 | -$79.5M | -1.9% |
| FY2016 | -$78.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice